Purpose: Positron emission tomography (PET) with radiolabeled amino acids provides information on biopsy target and chemotherapy response in patients with low-grade gliomas (LGG). In this article, we addressed whether PET with F-18 choline (CHO) detects increased metabolism in F-18 fluoroethyltyrosine (FET)-negative LGG patients. Methods: Six LGG patients with nongadolinium-enhancing (magnetic resonance) FET-negative LGG were imaged with CHO PET. Regions of interest were positioned over tumor and contralateral brain. Uptake of FET and CHO was quantified as count ratio of tumor to contralateral brain. Results: The mean FET uptake ratio for FET-negative LGG was 0.95 Ϯ 0.03 (mean Ϯ standard deviation). Five tumors did not show increased uptake ratios for CHO (0.96 Ϯ 0.12). Slightly increased CHO uptake was found in 1 patient (1.24), which, however, was not associated with tumor visualization. Conclusions: Amino acid and choline uptake appear to behave similar in nongadolinium-enhancing LGG. For clinical purposes, CHO PET is not superior to FET PET.
P ositron emission tomography (PET) with radiolabeled amino acids may provide important clinical information with regard to diagnostic aspects (biopsy, malignant transformation) and treatment follow-up in patients with low-grade gliomas ( LGG, World Health Organization grade II). 1, 2 However, several LGG patients are amino acid-"negative," which is defined as the absence of visually increased tracer uptake within a nongadolinium-enhancing T2-or FLAIR-intense lesion on magnetic resonance (MR) imaging. The issue how to image these amino acid-negative LGG has not been addressed. Radiolabeled deoxyglucose (F-18 fluorodeoxyglucose) as tracer for metabolic evaluation of LGG is limited due to the high biologic background of glucose metabolism in tumor surrounding normal brain. Proliferation tracers with low biologic background such as radiolabeled thymidine do not appear useful as they may be "negative" also in amino acid-positive LGG. 3 Several studies used choline PET and demonstrated a large range of choline uptake over the entire spectrum of gliomas. 4 -6 Here, we used F-18 choline (CHO) PET to image LGG in a series of patients who were previously amino acid-negative as shown with the amino acid analog F-18 fluoroethyltyrosine (FET). The rationale to use CHO in amino acid-negative LGG is given by the observation that choline uptake in normal brain of humans and animals is 3-to 4-fold lower than amino acid uptake, 5, 7 which could allow a better visualization of metabolically less active tumors with PET and CHO.
MATERIALS AND METHODS
We report on 6 consecutive patients with preoperatively suspected and histologically proven LGG. None of the tumors showed gadolinium enhancement on MR. All patients had a negative FET PET scan. No patient received previous radio-or chemotherapy.
PET with CHO was performed between 11 days and 6 weeks after the FET PET to detect metabolic tumor activity and to assist clinical decisions such as the definition of a biopsy target or assessment of chemotherapy response. Injected activities were 216 Ϯ 20 MBq for FET and 190 Ϯ 13 MBq for CHO (mean Ϯ standard deviation). The application of FET and CHO for PET was approved by the Swiss authorities (Swiss Medic), and patients gave their written consent.
The Philips ALLEGRO PET scanner was used in the 3D mode for acquisition of PET images. Images were reconstructed by a 3D row action maximum likelihood algorithm in a zoom mode for brain. Static FET PET scans were performed at 30 to 50 minutes after tracer injection (p.i.). 8 Regarding choline PET in brain tumors, various acquisition time periods between 2 and 40 minutes p.i. have been reported for PET scanning. 4 -6 Therefore, we decided to cover this time period by using 3 static PET scans, where the time frames ranged from 5 to 15 minutes, 20 to 30 minutes, and 35 to 45 minutes p.i. Calculated attenuation correction was applied by elliptical regions of interest (ROI) covering the entire skull. As MR FLAIR images provide a good delineation of LGG ROIs following the tumor contours were drawn in these MR sequences on the 2 adjacent planes, which showed the maximum lesion diameter. On the same planes, ROIs were mirrored to the contralateral brain for a reference ROI. The total ROI volume of the 2 planes (slice thickness, ranging between 6.3 and 7.2 mm) resulted in an average volume of interest of 26 cm 3 (range, 7-56 cm 3 ) for tumors and 26 cm 3 (7-54 cm 3 ) for the reference ROI in contralateral brain. The PET scans were then spatially normalized to the MR scans, and the ROIs were transferred on the FET and CHO PET scans. PET image counts were derived from each ROI, and uptake ratios of tumor to contralateral brain were calculated.
RESULTS
The clinical data and histologic diagnosis of the 6 LGG patients are presented in Table 1 . Their age was 48 Ϯ 7 years (mean Ϯ standard deviation). Tumor to contralateral brain uptake ratios for FET were 0.95 Ϯ 0.03 (Table 1) . By visual inspection, all FETnegative tumors were also CHO negative, which was reflected by overall low uptake ratios (Table 1) . One patient (1) showed a CHO uptake ratio of 1.24, which was not associated with "positive" tumor visualization or detection of metabolic hot spots (Fig. 1) . The time between CHO injection and data acquisition was irrelevant for the magnitude of CHO uptake ratios (Table 1 ).
DISCUSSION
Irrespective of the physiologically low background, CHO PET did not visualize FET-negative low-grade brain tumors. CHO was homogeneously distributed over all 6 tumors, and no metabolic "hot spot" was detected (Fig. 1 ). Kato et al 5 investigated patients with low-grade and malignant gliomas and reported parallel increases of C-11 methionine and CHO, which correlated well with tumor grade (mean uptake ratio World Health Organization II-III-IV: methionine 2.24 -3.03-5.03; CHO 2.69 -4.76 -18.35). That study did not separate "negative" from "positive" tumors. In our series, FET and CHO uptake ratios were about 1.0, thus reflecting a subgroup of LGG at a very low metabolic level. Pooling our and Kato et al's 5 data suggest that choline and amino acid behave similar over the range of all tumor grades. Overall, this implies that FET-negative LGG are expected not to exhibit increased metabolism on CHO PET. For the clinical purpose of biopsy and response evaluation, our data indicate that CHO PET does not render imaging results superior to FET PET in nonenhancing LGG.
It is not known whether CHO and FET-negative LGG follow a distinct biologic behavior. At the microscopical level, it was shown that the signal obtained with PET and FET in nonenhancing LGG represents a measure of microvascular density (MVD). 9 In addition, autoradiography in glioma bearing rats showed a correlation between choline uptake and tumor angiogenesis. 10 Kinetic PET studies on amino acids and choline demonstrated rapid tracer uptake into brain tumors of all grades, which is compatible with the view that the PET signal is derived from tumor vessels and reflects their transport across the blood-brain barrier. 8, 11 FET and CHO can therefore be viewed as surrogate markers of MVD. The in vivo information on the angiogenic potential could contribute to individual treatment decisions, and imaging of MVD by PET could be particularly useful in nonresectable tumors as their angiogenic potential cannot be assessed by representative tissue analysis. For example, antiangiogenic therapy may not be appropriate in CHO or FET PET-negative tumors, which would be interesting to address in a prospective study. Histology (WHO II): FIAC indicates fibrillary astrocytoma; OD, oligodendroglioma; OA, oligoastrocytoma. Uptake ratios represent the count ratios of tumor to contralateral brain for FET and CHO. CHO uptake ratios are presented for all 3 image acquisition periods. FIGURE 1. FET-negative low-grade glioma showing the highest CHO uptake ratio (1.24, patient 1). This uptake ratio was not associated with "positive" tumor visualization, but likely reflects the random variance of PET image with a low CHO background affecting the reference ROI in contralateral brain tissue. Corresponding planes of MR and PET images are shown. Gadolinium-enhanced T1 (A) and FLAIR (B) MR. PET with FET (C) and CHO (D).
